Manatt Health partner Helen Pfister spoke with Bloomberg Law about a new rule under review by the federal budget agency that would provide 340B covered entities and pharmaceutical manufacturers with a formal channel to resolve disputes relating to overcharges, duplicate discounts and diversion of 340B drugs. In the article, Pfister noted that, if passed, the rule likely won’t negate existing legal disputes over recent manufacturer actions limiting distribution of drugs to 340B contract pharmacies, saying, “promulgation of that rule is only one of many demands in the lawsuits.” She added that a similar lawsuit “requests, among other things, a declaration that 340B entities are ‘entitled’ to buy and distribute 340B drugs through pharmacies they contract with.”
Read the article here.